{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:58:02Z","timestamp":1787507882373,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), few data are available evaluating AF-specific care patterns and post-discharge outcomes in patients hospitalized for HFpEF. We evaluated AF-specific medical therapies and post-discharge outcomes among patients hospitalized for heart failure with mildly reduced ejection fraction (HFmrEF) or HFpEF by AF history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Trends in AF prevalence were evaluated among patients hospitalized for HFmrEF or HFpEF in the Get With The Guidelines-Heart Failure Registry from 2014 to 2020. Among those with linked Centers for Medicare &amp; Medicaid Services post-discharge data, we assessed associations of AF with 12-month outcomes and determined trends in post-discharge prescriptions. Among 429\u2009464 patients (median age 76\u2009years [interquartile range 65\u201385], 57% women), 216\u2009486 (50%) had a history of AF. Over time, the proportion of patients with AF increased slightly. Among the 79\u2009895 patients with post-discharge data, AF was independently associated with higher risk of mortality and all-cause readmissions at 12\u2009months, with stronger associations in HFpEF than in HFmrEF (mortality hazard ratio [HR] 1.13, 95% confidence interval [CI] 1.09\u20131.16 vs. HR 1.03, 95% CI 0.97\u20131.10; pinteraction = 0.009). Anti-arrhythmic drug use after heart failure hospitalization was low (18%) and increased modestly over time. Amiodarone accounted for 71% of total anti-arrhythmic drug prescriptions. Overall use of anticoagulants after heart failure hospitalization has significantly increased from 52% in 2014 to 61% in 2019, but remained modest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prevalence of AF is rising among patients hospitalized with HFpEF. Those with comorbid AF face elevated post-discharge risks of death and rehospitalization. Current use of pharmacological rhythm control is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2729","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T14:45:05Z","timestamp":1667832305000},"page":"63-73","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Intersection of Atrial Fibrillation and Heart Failure with Mildly Reduced and Preserved Ejection Fraction in &amp;gt;400 000 Participants in the Get With The Guidelines-Heart Failure Registry"],"prefix":"10.1093","volume":"25","author":[{"given":"Ravi B.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Xu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Denver Health Medical Center , Denver, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Piccini","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Anschutz Medical Center , Aurora, CO ,","place":["USA"]},{"name":"Ahmanson-University of California, Los Angeles Cardiomyopathy Center, University of California-Los Angeles , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,20]]},"reference":[{"key":"2026010913081975200_ejhf2729-bib-0001","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jchf.2018.09.008","article-title":"History of atrial fibrillation and trajectory of decongestion in acute heart failure","volume":"7","author":"Patel","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0003","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2022.01.018","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"10","author":"Cikes","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0004","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2022.08.718","article-title":"Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0005","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1093\/eurheartj\/ehy626","article-title":"Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"39","author":"Zafrir","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913081975200_ejhf2729-bib-0006","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchf.2018.05.005","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"6","author":"Cikes","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0008","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1038\/s41598-021-84133-9","article-title":"Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study","volume":"11","author":"Patel","year":"2021","journal-title":"Sci Rep"},{"key":"2026010913081975200_ejhf2729-bib-0009","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0010","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.hpc.0000243588.00012.79","article-title":"Overview of the American Heart Association \u201cGet With The Guidelines\u201d programs: coronary heart disease, stroke, and heart failure","volume":"5","author":"Hong","year":"2006","journal-title":"Crit Pathw Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913081975200_ejhf2729-bib-0013","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913081975200_ejhf2729-bib-0014","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","article-title":"Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"5","author":"Sartipy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijcard.2018.02.007","article-title":"Atrial fibrillation and heart failure with preserved ejection fraction: insights on a unique clinical phenotype from a nationally-representative United States cohort","volume":"266","author":"Goyal","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0016","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/heartjnl-2019-316219","article-title":"Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction","volume":"106","author":"Son","year":"2020","journal-title":"Heart"},{"key":"2026010913081975200_ejhf2729-bib-0017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamacardio.2020.0136","article-title":"Therapeutic targeting of left atrial myopathy in atrial fibrillation and heart failure with preserved ejection fraction","volume":"5","author":"Patel","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.119.042996","article-title":"Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0019","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchf.2016.10.005","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume","volume":"5","author":"Lam","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","article-title":"Early rhythm control therapy in patients with atrial fibrillation and heart failure","volume":"144","author":"Rillig","year":"2021","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0021","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ejhf.2487","article-title":"Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913081975200_ejhf2729-bib-0022","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011560","article-title":"Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from Get With The Guidelines-Heart Failure","volume":"8","author":"Kelly","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026010913081975200_ejhf2729-bib-0024","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"Kober","year":"2008","journal-title":"N Engl J Med"},{"key":"2026010913081975200_ejhf2729-bib-0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS Fuideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0026","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of beta-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913081975200_ejhf2729-bib-0027","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1161\/CIRCULATIONAHA.118.035909","article-title":"Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable","volume":"139","author":"Piccini","year":"2019","journal-title":"Circulation"},{"key":"2026010913081975200_ejhf2729-bib-0028","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/ehf2.13264","article-title":"Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type","volume":"8","author":"Uhm","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/1\/63\/65493603\/eurjhf_25_1_63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/1\/63\/65493603\/eurjhf_25_1_63.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:10:13Z","timestamp":1767982213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/1\/63\/8341719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,20]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2729","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,11,20]]},"assertion":[{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}